BLAIV (INFUSION)INJECTABLE
Approved
Sep 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
102
Data completeness
5/8 — Partial
VECTIBIX (panitumumab) by Amgen is her1 antagonists [moa]. Approved for epidermal growth factor receptor antagonist [epc]. First approved in 2006.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VECTIBIX (panitumumab) is a fully human monoclonal antibody that antagonizes the epidermal growth factor receptor (EGFR/HER1), blocking ligand-induced cell proliferation and survival signaling. It is indicated across 14 tumor types, including metastatic colorectal cancer, head and neck squamous cell carcinoma, pancreatic cancer, and non-small cell lung cancer. The drug works by binding to EGFR and preventing downstream signaling that drives tumor growth.
$4.0MPart D
LOE ApproachingStable
Product is in late-stage lifecycle with modest Medicare utilization (351 Part D claims in 2023), signaling a smaller, stable-to-declining brand team.
Mechanism of Action
HER1 Antagonists
Pharmacologic Class:
Epidermal Growth Factor Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (102)
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Started Jan 2026
14 enrolled
Advanced Solid Tumors
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Started Apr 2025
390 enrolled
Metastatic Colorectal Cancer
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Started Jul 2024
450 enrolled
Metastatic Colorectal Cancer
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
Started Apr 2022
160 enrolled
Colorectal Cancer (CRC)
PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence
Started Dec 2020
214 enrolled
Colorectal Cancer
Worked on VECTIBIX at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.